In a strategic move, Edwards Lifesciences has agreed to sell its critical care portfolio for $4.2 billion in cash to BD (Becton, Dickinson and Company), a healthcare technology company based in New Jersey. Originally, Edwards had planned to spin off its critical care business, but instead, the company is now focusing on developing new structural heart technologies and expanding offerings in areas like transcatheter aortic valve replacement (TAVR) and tricuspid valve replacement.
BD’s chairman, CEO, and president, Tom Polen, highlighted that the transaction is expected to have an immediate positive impact on key financial measures and offer a strong return profile. He emphasized BD’s ongoing commitment to delivering sustained shareholder value and expressed belief that the transaction will strengthen both Edwards, critical care, and BD, ultimately leading to greater value for patients.
Bernard Zovighian, CEO of Edwards Lifesciences, stated that the decision to separate critical care aligns with the company’s strategy of focusing on structural heart disease. He emphasized the company’s goal of using innovative technologies to address unmet patient needs, extend global leadership, drive sustainable growth, and increase shareholder value. He also noted the significant contributions critical care has made to Edwards and its history of pioneering innovation
